BioScript - Important Update to the Enhertu™ DESTINY-Breast03 Patient Support Program

Home > Important Update to the Enhertu™ DESTINY-Breast03 Patient Support Program - May 24

Dear Health Care Provider,

As a healthcare provider who has previously enrolled patients in the AstraZeneca Oncology Patient Support Program (PSP) for Enhertu, we are writing to inform you of an extension to the free drug component for the DESTINY-Breast 03 indication (i.e., adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed recurrence during or within 6 months of completing therapy) to August 1, 2023.

As you may recall from our initial communication, the free drug component of this PSP was scheduled to close to new patients as of June 1, 2023, and we are pleased to be able to support patient access to this treatment for an additional two months as we continue to work toward public reimbursement.

With the extension of the free drug component of the PSP for eligible Enhertu patients until August 1, 2023, please note the following refinements to the program:

All eligible patients enrolled in the free drug component of the PSP by end of day August 1, 2023 will continue to receive free drug through the PSP until disease progression, or public reimbursement, whichever is earlier.

After August 1, 2023, all NEW eligible patients enrolled in the PSP will still have access to educational resources, reimbursement navigation, infusion support and co-payment support toward the cost of Enhertu (up to 20%). The free drug component of the Enhertu DESTINY-Breast03 PSP will no longer be available.

While we work towards public access for Enhertu DESTINY-Breast03, we will continue to provide updates on the status of the PSP free drug program for eligible patients enrolled on or before August 1, 2023. Once provincial coverage is established for Enhertu DESTINY-Breast03, the PSP will notify clinicians at the time of listing and support with the transition of these patients to the publicly funded supply of Enhertu.

Please note, there are no changes at this time to the PSP offerings for the DESTINY-Breast01 or DESTINY-Breast04 indications. As a reminder, the DESTINY-Breast01 free drug program closed May 31, 2022, and the free drug program for treatment eligible DESTINY-Breast04 patients is scheduled to close January 31, 2024. Should there be any changes to these programs, prescribing physicians will be notified in advance.

For questions about the PSP or to enroll a patient, please call 1-877-280-6208 (Monday through Friday, 8 a.m. to 8 p.m. ET) or email enrollment@azoncologypsp.ca. If you have any questions about Enhertu, please contact your local AstraZeneca representative.

Regards,
Your Patient Care Coordinator
AstraZeneca Oncology Patient Support Program